{"log_id": 8049021718683010960, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 0.002212, "average": 0.980556, "min": 0.776584}, "location": {"width": 859, "top": 227, "height": 60, "left": 190}, "words": "为45例每1000名妇女每年,与之相对,安慰剂组为21例每1000名妇女每年(RR2.05"}, {"probability": {"variance": 0.005678, "average": 0.951028, "min": 0.700421}, "location": {"width": 490, "top": 270, "height": 48, "left": 193}, "words": "95%CI121-3.48)(见[注意事项]一警告,痴呆)"}, {"probability": {"variance": 5.7e-05, "average": 0.995973, "min": 0.970745}, "location": {"width": 776, "top": 312, "height": 58, "left": 240}, "words": "阿尔采默氏病在两个治疗组和安慰剂组都是可能性痴呆的最常见分类。在CEE组"}, {"probability": {"variance": 0.000115, "average": 0.995659, "min": 0.946321}, "location": {"width": 841, "top": 340, "height": 62, "left": 194}, "words": "79%的可能性痴呆发生在70岁以上的妇女中。在CE加MPA组,70岁以上妇女发生可"}, {"probability": {"variance": 0.000196, "average": 0.995189, "min": 0.923063}, "location": {"width": 696, "top": 377, "height": 53, "left": 192}, "words": "能性痴呆,占全部可能性痴呆病例的82%(见[注意事项]一警告,痴呆"}, {"probability": {"variance": 6.3e-05, "average": 0.995964, "min": 0.959113}, "location": {"width": 808, "top": 426, "height": 57, "left": 241}, "words": "汇总倍美力或倍美安组患者的数据,与安慰剂组相比较,使用ERT或HRT发生可"}, {"probability": {"variance": 0.005192, "average": 0.979511, "min": 0.524567}, "location": {"width": 844, "top": 456, "height": 58, "left": 193}, "words": "能性痴呆的绝对风险是41例每10,000妇女每年,与之对应安慰剂组为23例每10,000妇"}, {"probability": {"variance": 0.00137, "average": 0.986295, "min": 0.742813}, "location": {"width": 854, "top": 486, "height": 57, "left": 194}, "words": "女每年(RR1.76,95%CI1.19-2.60)。鉴于两项子研究都针对65-79岁妇女,尚不清楚上"}, {"probability": {"variance": 0.000729, "average": 0.988726, "min": 0.884036}, "location": {"width": 729, "top": 519, "height": 54, "left": 195}, "words": "述结果是否适用于比较年轻的绝经后妇女。(见[注意事项]一警告,痴呆)"}, {"probability": {"variance": 0.000932, "average": 0.993909, "min": 0.813514}, "location": {"width": 792, "top": 570, "height": 55, "left": 244}, "words": "关于已批准的适应症的有效性方面,还没有对足够数量的老年患者进行研究以证实"}, {"probability": {"variance": 1.3e-05, "average": 0.998084, "min": 0.984574}, "location": {"width": 670, "top": 603, "height": 54, "left": 198}, "words": "65岁以上的老年人与较年轻的受试者相比,对倍美力的反应是否不同"}, {"probability": {"variance": 0.049695, "average": 0.840965, "min": 0.525707}, "location": {"width": 126, "top": 650, "height": 38, "left": 907}, "words": "制药有"}, {"probability": {"variance": 0.000283, "average": 0.989137, "min": 0.951603}, "location": {"width": 173, "top": 677, "height": 34, "left": 197}, "words": "[药物相互作用]"}, {"probability": {"variance": 0.011227, "average": 0.97096, "min": 0.463129}, "location": {"width": 800, "top": 681, "height": 58, "left": 247}, "words": "单一剂量的药物(包括结合雌激素和醋酸甲羟孕酮)-药物之间相互作用的研究资料"}, {"probability": {"variance": 5.1e-05, "average": 0.997431, "min": 0.957464}, "location": {"width": 860, "top": 710, "height": 61, "left": 196}, "words": "表明,同时服用这两种药时,药代动力学分布不会改变。临床上没有进行其它的与结合雌"}, {"probability": {"variance": 1e-06, "average": 0.999149, "min": 0.995389}, "location": {"width": 356, "top": 758, "height": 41, "left": 197}, "words": "激素有关的药物之间的相互作用研究"}, {"probability": {"variance": 0.00111, "average": 0.972696, "min": 0.915232}, "location": {"width": 154, "top": 745, "height": 46, "left": 901}, "words": "西药商务"}, {"probability": {"variance": 0.003459, "average": 0.987393, "min": 0.621835}, "location": {"width": 767, "top": 797, "height": 54, "left": 249}, "words": "体内外研究都表明雌激素部分通过细胞色素P4503A4(CYP3A4)来代谢。因此"}, {"probability": {"variance": 0.00014, "average": 0.995784, "min": 0.924532}, "location": {"width": 850, "top": 824, "height": 59, "left": 202}, "words": "CYP3A4的诱导剂和抑制剂都能影响雌激素药物的代谢。CYP3A4的诱导剂如圣约翰草提"}, {"probability": {"variance": 0.00094, "average": 0.993078, "min": 0.80487}, "location": {"width": 861, "top": 852, "height": 61, "left": 198}, "words": "取物(贯叶连翘)、苯巴比妥、卡马西平和利福平都可以降低雌激素血浆浓度,可能导致"}, {"probability": {"variance": 0.000369, "average": 0.995501, "min": 0.877256}, "location": {"width": 842, "top": 882, "height": 59, "left": 200}, "words": "治疗效果降低和或改变子宫出血的情况。CYP3A4的抑制剂如红霉素、克拉霉素、酮康"}, {"probability": {"variance": 0.00017, "average": 0.994768, "min": 0.949485}, "location": {"width": 771, "top": 915, "height": 54, "left": 200}, "words": "唑、伊曲康唑、利托那韦和葡萄柚汁可以升高雌激素血浆浓度,而引起不良反应"}, {"probability": {"variance": 0.00126, "average": 0.980347, "min": 0.909437}, "location": {"width": 111, "top": 992, "height": 30, "left": 202}, "words": "[药物过量"}, {"probability": {"variance": 3.1e-05, "average": 0.998236, "min": 0.966392}, "location": {"width": 791, "top": 997, "height": 55, "left": 252}, "words": "在成人及儿童中,过量服用含雌激素药物的症状包括:恶心、呕吐、乳房触痛、头"}, {"probability": {"variance": 0.001044, "average": 0.991026, "min": 0.795099}, "location": {"width": 842, "top": 1026, "height": 58, "left": 203}, "words": "昏、腹痛、嗜睡/疲劳;女性可出现撤退性出血。尚无特殊解毒药,必要时应采取对症治"}, {"probability": {"variance": 0, "average": 0.999239, "min": 0.999239}, "location": {"width": 24, "top": 1086, "height": 24, "left": 204}, "words": "疗"}, {"probability": {"variance": 0.000667, "average": 0.977682, "min": 0.92306}, "location": {"width": 125, "top": 1134, "height": 36, "left": 206}, "words": "[临床试验]"}, {"probability": {"variance": 0.000122, "average": 0.993896, "min": 0.964869}, "location": {"width": 184, "top": 1164, "height": 36, "left": 206}, "words": "妇女健康行动研究"}, {"probability": {"variance": 0.007758, "average": 0.970469, "min": 0.543148}, "location": {"width": 774, "top": 1169, "height": 58, "left": 254}, "words": "妇女健康行动(WHI)入选了约27,00名大多健康的绝经后妇女进入两个亚组研"}, {"probability": {"variance": 0.003172, "average": 0.979346, "min": 0.748424}, "location": {"width": 848, "top": 1199, "height": 56, "left": 206}, "words": "究:来评价与安慰剂相比结合雌激素(CEE)[倍美力每天0.625mg]单独使用或与醋酸甲"}, {"probability": {"variance": 0.012408, "average": 0.967427, "min": 0.37678}, "location": {"width": 821, "top": 1229, "height": 55, "left": 206}, "words": "羟孕酮(MPA)联合使用(每天0.625mg/2.5mg)的风险与受益主要终点为冠心病"}, {"probability": {"variance": 0.005154, "average": 0.980112, "min": 0.572492}, "location": {"width": 836, "top": 1256, "height": 57, "left": 216}, "words": "(CHD)的发生率,如非致死性心肌梗塞(MI),无症状心肌梗塞和冠心病死亡。主要"}, {"probability": {"variance": 0.000785, "average": 0.994351, "min": 0.8338}, "location": {"width": 746, "top": 1287, "height": 55, "left": 208}, "words": "安全终点为侵润性乳腺癌的发生率。该研究没有评估倍美力对绝经症状的作用"}, {"probability": {"variance": 0.00013, "average": 0.995192, "min": 0.944554}, "location": {"width": 812, "top": 1338, "height": 56, "left": 258}, "words": "因为观察到中风的风险增加,而且认为在预先设定的主要终点上不会获得更多有关单"}, {"probability": {"variance": 0.001699, "average": 0.991384, "min": 0.737914}, "location": {"width": 860, "top": 1367, "height": 59, "left": 209}, "words": "用雌激素的风险和受益的信息,所以单用雌激素组被提前中止。单用雌激素组研究共包括"}, {"probability": {"variance": 0.011426, "average": 0.953359, "min": 0.45064}, "location": {"width": 839, "top": 1399, "height": 56, "left": 210}, "words": "10739名妇女(年龄50-79,平均63岁:75.3%为白人,15.1%为黑人,61%为西班牙人"}, {"probability": {"variance": 0.037957, "average": 0.884533, "min": 0.417974}, "location": {"width": 433, "top": 1438, "height": 46, "left": 209}, "words": "3.5%为其他,平均随访68年,结果见表1"}, {"probability": {"variance": 0.03574, "average": 0.801192, "min": 0.480937}, "location": {"width": 580, "top": 1486, "height": 49, "left": 262}, "words": "在WHI羊用雌激素:对H的相对风险(RR)9"}, {"probability": {"variance": 0.02879, "average": 0.826573, "min": 0.542183}, "location": {"width": 179, "top": 1482, "height": 26, "left": 903}, "words": "名义可信区间nC"}, {"probability": {"variance": 0.019081, "average": 0.896918, "min": 0.46879}, "location": {"width": 846, "top": 1509, "height": 57, "left": 210}, "words": "0.79-1.16)总体上没有显著影响。在访早期报去有心D相对险的轻摩增加随时间"}], "language": 3}